View Future GrowthThis company is no longer activeThe company may no longer be operating, as it may be out of business. Find out why through their latest events.See Latest EventsMurphy Canyon Acquisition 過去の業績過去 基準チェック /26Murphy Canyon Acquisition は平均年間 196.2% の収益成長を遂げていますが、Capital Markets 業界では年間 収益成長率 となっています。6.3% です。主要情報196.19%収益成長率n/aEPS成長率Capital Markets 業界の成長10.26%収益成長率n/a株主資本利益率n/aネット・マージンn/a前回の決算情報30 Jun 2023最近の業績更新更新なしすべての更新を表示Recent updatesお知らせ • Sep 22Murphy Canyon Acquisition Corp., Conduit Merger Sub, Inc and Conduit Pharmaceuticals Limited Approve Board ElectionsMurphy Canyon Acquisition Corp. announced that at its EGM held on September 20, 2023, the shareholders approved election of Freda Lewis-Hall, David Tapolczay, James Bligh, Faith L. Charles, Chele Chiavacci Farley, Jennifer I. McNealey, and Andrew Regan as directors of New Conduit. The business combination (the Business Combination), as amended and supplemented, including the Agreement and Plan of Merger, dated as of November 8, 2022 and as amended on January 27, 2023 and May 11, 2023 (the Merger Agreement), by and among the company, Conduit Pharmaceuticals Limited (Conduit) and Conduit Merger Sub Inc. (Merger Sub), which, among other things, provides for the merger of Merger Sub with and into Conduit, with Conduit surviving the merger as a wholly-owned subsidiary of the company.お知らせ • Nov 10Conduit Pharmaceuticals Limited entered into a definitive Business Combination Agreement to acquire Murphy Canyon Acquisition Corp. (NasdaqGM:MURF) for $650 million in a reverse merger agreement.Conduit Pharmaceuticals Limited entered into a definitive Business Combination Agreement to acquire Murphy Canyon Acquisition Corp. (NasdaqGM:MURF) for $650 million in a reverse merger agreement on November 8, 2022. Murphy Canyon shall issue and deliver to the shareholders of Conduit an aggregate number of shares of Murphy Canyon’s common stock with an aggregate value equal to $650 million, with each share valued at $10.00 per share. The combined company is anticipated to have an estimated pro forma enterprise valuation of approximately $700.49 million. A private placement transaction shall be conducted by Murphy Canyon contemporaneously with the Business Combination (the “PIPE Financing”), pursuant to which Murphy Canyon has entered into subscription agreements providing for aggregate investments in Murphy Canyon’s securities of $27 million. The PIPE Investment is expected to close in connection with the business combination and is subject to the satisfaction of other customary closing conditions and a NASDAQ listing. After the closing of the Transactions and assuming no redemptions by Murphy’s public stockholders, existing Conduit shareholders will retain 100% of their equity ownership and will own approximately 76.48% of the pro forma combined company. The Company is expected to be renamed Conduit Pharmaceuticals Inc. at the closing of the Business Combination and is anticipated to be listed on NASDAQ under ticker symbol “CDT”. The combined company will continue to operate under the Conduit management team, led by David Tapolczay, Chief Executive Officer, and Freda Lewis-Hall, Chair of the Board of Directors. The Transactions, which have been unanimously approved by the boards of directors of both Conduit and Murphy, are subject to, among other customary closing conditions, approval by the stockholders of Murphy, and the shareholders of Conduit. The transaction is expected to close in the first quarter of 2023. Cash proceeds from the transaction are expected to consist of up to approximately $136.04 million of cash held in Murphy’s trust account and approximately $27 million attributable to a private investment anchored by new and existing investors of Conduit. A.G.P./Alliance Global Partners is serving as exclusive financial advisor to Conduit and Murphy. Thompson Hine LLP is serving as legal advisor to Conduit and Sichenzia Ross Ference LLP is serving as legal advisor to Murphy.お知らせ • Nov 09Murphy Canyon Acquisition Corp. announced that it expects to receive $27 million in fundingMurphy Canyon Acquisition Corp. announced that it has entered into subscription agreement for a private placement of $27,000,000 on November 8, 2022.お知らせ • May 17Murphy Canyon Acquisition Corp. announced delayed 10-Q filingOn 05/16/2022, Murphy Canyon Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.Seeking Alpha • Apr 04Murphy Canyon Acquisition Seeks Deal With Real Estate Proptech CompanyMurphy Canyon Acquisition Corp. went public recently, raising $132 million in an IPO. The SPAC seeks to merge with a company in the real estate Proptech industry. While MURF management has extensive industry experience, they don't have a previous SPAC track record, so I'm on Hold for the SPAC.収支内訳Murphy Canyon Acquisition の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史NasdaqGM:MURF 収益、費用、利益 ( )USD Millions日付収益収益G+A経費研究開発費30 Jun 23012031 Mar 23011031 Dec 220010質の高い収益: MURFは 高品質の収益 を持っています。利益率の向上: MURFの 利益率 が過去 1 年間で改善したかどうかを判断するにはデータが不十分です。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: MURFは株式公開されてから 3 年未満しか経っていないため、過去 5 年間の前年比収益成長率がプラスであったかどうかを判断できません。成長の加速: MURFは株式公開されてから 3 年未満であるため、過去 1 年間の収益成長を 5 年間の平均と比較することはできません。収益対業界: MURFの過去 1 年間の収益成長率 ( 196.2% ) はCapital Markets業界36.2%を上回りました。株主資本利益率高いROE: MURFの負債は資産を上回っているため、自己資本利益率を計算することは困難です。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YDiversified-financials 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2023/09/23 09:39終値2023/09/22 00:00収益2023/06/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Murphy Canyon Acquisition Corp. これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Sep 22Murphy Canyon Acquisition Corp., Conduit Merger Sub, Inc and Conduit Pharmaceuticals Limited Approve Board ElectionsMurphy Canyon Acquisition Corp. announced that at its EGM held on September 20, 2023, the shareholders approved election of Freda Lewis-Hall, David Tapolczay, James Bligh, Faith L. Charles, Chele Chiavacci Farley, Jennifer I. McNealey, and Andrew Regan as directors of New Conduit. The business combination (the Business Combination), as amended and supplemented, including the Agreement and Plan of Merger, dated as of November 8, 2022 and as amended on January 27, 2023 and May 11, 2023 (the Merger Agreement), by and among the company, Conduit Pharmaceuticals Limited (Conduit) and Conduit Merger Sub Inc. (Merger Sub), which, among other things, provides for the merger of Merger Sub with and into Conduit, with Conduit surviving the merger as a wholly-owned subsidiary of the company.
お知らせ • Nov 10Conduit Pharmaceuticals Limited entered into a definitive Business Combination Agreement to acquire Murphy Canyon Acquisition Corp. (NasdaqGM:MURF) for $650 million in a reverse merger agreement.Conduit Pharmaceuticals Limited entered into a definitive Business Combination Agreement to acquire Murphy Canyon Acquisition Corp. (NasdaqGM:MURF) for $650 million in a reverse merger agreement on November 8, 2022. Murphy Canyon shall issue and deliver to the shareholders of Conduit an aggregate number of shares of Murphy Canyon’s common stock with an aggregate value equal to $650 million, with each share valued at $10.00 per share. The combined company is anticipated to have an estimated pro forma enterprise valuation of approximately $700.49 million. A private placement transaction shall be conducted by Murphy Canyon contemporaneously with the Business Combination (the “PIPE Financing”), pursuant to which Murphy Canyon has entered into subscription agreements providing for aggregate investments in Murphy Canyon’s securities of $27 million. The PIPE Investment is expected to close in connection with the business combination and is subject to the satisfaction of other customary closing conditions and a NASDAQ listing. After the closing of the Transactions and assuming no redemptions by Murphy’s public stockholders, existing Conduit shareholders will retain 100% of their equity ownership and will own approximately 76.48% of the pro forma combined company. The Company is expected to be renamed Conduit Pharmaceuticals Inc. at the closing of the Business Combination and is anticipated to be listed on NASDAQ under ticker symbol “CDT”. The combined company will continue to operate under the Conduit management team, led by David Tapolczay, Chief Executive Officer, and Freda Lewis-Hall, Chair of the Board of Directors. The Transactions, which have been unanimously approved by the boards of directors of both Conduit and Murphy, are subject to, among other customary closing conditions, approval by the stockholders of Murphy, and the shareholders of Conduit. The transaction is expected to close in the first quarter of 2023. Cash proceeds from the transaction are expected to consist of up to approximately $136.04 million of cash held in Murphy’s trust account and approximately $27 million attributable to a private investment anchored by new and existing investors of Conduit. A.G.P./Alliance Global Partners is serving as exclusive financial advisor to Conduit and Murphy. Thompson Hine LLP is serving as legal advisor to Conduit and Sichenzia Ross Ference LLP is serving as legal advisor to Murphy.
お知らせ • Nov 09Murphy Canyon Acquisition Corp. announced that it expects to receive $27 million in fundingMurphy Canyon Acquisition Corp. announced that it has entered into subscription agreement for a private placement of $27,000,000 on November 8, 2022.
お知らせ • May 17Murphy Canyon Acquisition Corp. announced delayed 10-Q filingOn 05/16/2022, Murphy Canyon Acquisition Corp. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
Seeking Alpha • Apr 04Murphy Canyon Acquisition Seeks Deal With Real Estate Proptech CompanyMurphy Canyon Acquisition Corp. went public recently, raising $132 million in an IPO. The SPAC seeks to merge with a company in the real estate Proptech industry. While MURF management has extensive industry experience, they don't have a previous SPAC track record, so I'm on Hold for the SPAC.